Semalytix GmbH, based in Bielefeld, Germany, offers an Agentic AI platform that lets pharmaceutical teams compliantly tap into the "global patient voice" and embed those insights directly into drug-development workflows. Powered by PatientGPT, the company’s Atlas platform aggregates 100 million public social data points, 33 million medical publications, and more than 400,000 clinical-trial outcomes to create role-specific AI agents for pharma users. Its "Agent-as-a-Service" approach allows clients to build proprietary AI models and compounding intellectual property rather than relying on one-off research projects. Semalytix has already secured commercial traction with several top-20 pharmaceutical companies. With the majority of pharma workflows estimated to be 75–85 % automatable or augmentable by AI, management believes the addressable market is large and urgent. Proceeds from the latest funding will be used to enhance the platform’s capabilities, grow the AI, customer-success, and commercial teams, and expand internationally, particularly across Europe and the United States.

Total raised

$14M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2025